2.71
0.01 (0.37%)
| Previous Close | 2.70 |
| Open | 2.72 |
| Volume | 2,207,278 |
| Avg. Volume (3M) | 625,085 |
| Market Cap | 268,912,480 |
| Price / Sales | 3.65 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 19 Aug 2025 |
| Profit Margin | -197.64% |
| Operating Margin (TTM) | -123.58% |
| Diluted EPS (TTM) | -1.42 |
| Quarterly Revenue Growth (YOY) | 27.60% |
| Current Ratio (MRQ) | 4.46 |
| Operating Cash Flow (TTM) | -136.07 M |
| Levered Free Cash Flow (TTM) | -110.34 M |
| Return on Assets (TTM) | -27.02% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | ADC Therapeutics SA | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -1.5 |
| Average | 0.30 |
|
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 21.59% |
| % Held by Institutions | 67.58% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Redmile Group, Llc | 31 Mar 2025 | 15,666,731 |
| Prosight Management, Lp | 31 Mar 2025 | 9,543,004 |
| Orbimed Advisors Llc | 31 Mar 2025 | 5,968,451 |
| Vantage Consulting Group Inc | 31 Mar 2025 | 850,737 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 10.00 (Guggenheim, 269.00%) | Buy |
| Median | 8.00 (195.20%) | |
| Low | 5.00 (RBC Capital, 84.50%) | Buy |
| Average | 7.67 (183.03%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 2.59 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 20 Jun 2025 | 5.00 (84.50%) | Buy | 2.77 |
| 15 May 2025 | 8.00 (195.20%) | Buy | 1.69 | |
| Guggenheim | 13 Jun 2025 | 10.00 (269.00%) | Buy | 3.58 |
| 31 Mar 2025 | 7.00 (158.30%) | Buy | 1.41 | |
| HC Wainwright & Co. | 31 Mar 2025 | 8.00 (195.20%) | Buy | 1.41 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |